Monoclonal antibodies targeting cluster designation (CD) surface molecules CD33, CD123, CD70, CLL1 (or CLEC12a), TIM3, WT1 and others, may result in important anti-AML efficacy. This evidence concerns the gene CD33 and acute myeloid leukemia.